Personal Stories from TB Survivors - My Journey fighting TB
South African Study Transforms Global TB Treatment
Tuberculosis remains a critical public health issue in many countries and is a leading cause of death in South Africa. Over the past six years, the BEAT Tuberculosis study, conducted in South Africa and focused on children and pregnant women, has revealed a promising new oral treatment that could mark a significant breakthrough in the fight against drug-resistant TB. Zaheer Cassim reports.
New York: Anupriya Patel Advocates For Innovative TB Vaccines, Highlights Nation's Progress In TB Elimination
Union Minister of State, Anupriya Patel, during her address at the 'Interactive TB Vaccines Dialogue' event in New York, highlighted the severity of tuberculosis and across the world, and advocated for innovative TB vaccines.The MoS for Health and Family Welfare delivered the keynote address at the event on the sidelines of the 79th United Nations General Assembly in New York on Tuesday.
In her address, Patel highlighted India's role as the chair of the Stop TB Partnership Board and reiterated the nation's commitment to eliminating TB as a public health problem by 2030. She said that India's TB program has become a "model for the world."
She stated that India had seen a decline of TB occurrences by 16 per cent and an 18 per cent reduction in TB deaths in 2022 in comparison to the rates back in 2015.
"India is progressing against the Sustainable Development Goals (SDG) at a far greater pace than the global average, with a decline in TB incidence by 16 per cent from 237 per hundred thousand population in 2015 to 199 in 2022 and a decline of 18 per cent in TB deaths from 28 per hundred thousand population in 2015 to 23 in 2022," she said.
Referencing to the National Strategic Plan that had scaled up TB services in India, Patel said, "Under the visionary leadership of Prime Minister Shri Narendra Modi, India has made remarkable strides in TB care and prevention, from infrastructure expansion to financial support for patients."
She further stated that India's TB programme has seen a treatment success rate of 88 per cent and that it has become a "model to the world."
Patel also highlighted that under the National Tuberculosis Elimination Programme (NTEP), a total of USD 373 million has been provided to 10 million TB patients in India.
"With over 7,767 molecular diagnostic laboratories, cutting-edge treatment protocols, and an 88 per cent treatment success rate, India's TB program has become a model for the world. India initiated Nikshay Poshan Yojana in 2018 for providing $6 USD/month to support nutrition of TB patients for the entire duration of treatment. Cumulatively, till Aug 2024, NTEP has disbursed 373 million USD to more than 10 million TB patients," she added.
Emphasising the critical need for new vaccines, Patel stated, "TB has been the worst killer among all infectious diseases. While the childhood BCG vaccine has been essential in protecting children, its protective effects diminish with age... Despite our advances, the world still loses millions of lives to TB. So, the time to invest in innovative vaccines is now."
Highlighting the "urgent need for an innovative and effective TB vaccine," Patel said, "the unmet need for a TB vaccine and its potential role in TB elimination is where the world is focusing now and this forum represents a critical opportunity for us to come together, share knowledge, and accelerate the development of these life-saving vaccines."
"With around 16 vaccines having entered clinical trial assessments, the future of TB vaccine development looks considerably brighter than before," she added.
She also highlighted India's Research and Development (R&D) with recombinant BCG VPM1002 and Immuvac, the ongoing trial for evaluation of BCG revaccination in adults, and another trial in Phase IIb with novel vaccine MTBVAC ongoing among adults.
Underlining the importance of the Stop TB Partnership, Patel later said, "The partnership is a beacon of collective strength and has evolved into a global force comprising over 2,000 partners from diverse sectors, all united in our resolve to eliminate TB as a public health problem by 2030." (ANI)
Tuberculosis Diagnostics Test Market To Hit USD 3.7 Billion By 2032, Says Global Market Insights Inc.
Global Market Insights Inc.
Tuberculosis diagnostics test industry is projected to witness a CAGR of 5.5% during the period 2024-2032. This growth can be attributed to advancement in tuberculosis diagnostics techniques.
Selbyville, Delaware, Sept. 23, 2024 (GLOBE NEWSWIRE) --
Tuberculosis Diagnostics Test Market size will reach USD 3.7 Billion by 2032. Technological advancements in tuberculosis diagnostics are significantly enhancing industry progression by improving the accuracy and efficiency of disease detection.
Request for a sample of this research report @ https://www.Gminsights.Com/request-sample/detail/7892
Molecular diagnostics, such as nucleic acid amplification tests (NAATs), and innovations such as GeneXpert have revolutionized TB testing by providing rapid and reliable results. These technologies reduce the time required for diagnosis, enabling earlier treatment and better patient outcomes. The Global Fund noted that in 2024, investments in new TB diagnostic technologies, including GeneXpert and other molecular tests, have increased by 30% compared to the previous year.
Additionally, the development of rapid point-of-care tests allows for TB detection in resource-limited settings, further expanding access to diagnostics. As these technologies continue to evolve, they play a crucial role in ushering in the global market.
Radiographic test to gain popularity for TB detection
The tuberculosis diagnostics test market from radiographic segment will grow rapidly during the forecast period, due to their effectiveness in detecting TB, particularly in patients with non-specific or asymptomatic presentations. Radiographic techniques, such as chest X-rays, are increasingly utilized in large-scale screening programs, especially in high-risk populations. These methods provide a non-invasive and relatively quick way to identify pulmonary TB, aiding in early diagnosis and intervention. Additionally, advancements in digital radiography are improving image quality and diagnostic accuracy, further boosting their adoption in TB detection efforts worldwide.
POCT adoption to address tb burden in remote communities
The tuberculosis diagnostics test market from point-of-care testing (POCT) segment will witness decent development between 2024 to 2032, owing to the growing need for rapid and accessible testing in remote and resource-limited areas. POCT enables immediate diagnosis and treatment decisions, significantly reducing the time between testing and care. This is particularly critical in regions with limited laboratory infrastructure where traditional testing methods are less feasible. Furthermore, POCT supports large-scale screening efforts by providing quick results, which is essential for controlling TB spread in high-burden communities.
Story continues
Resurgence of TB boosts diagnostic demand in Europe
Europe tuberculosis diagnostics test market size will expand at a notable pace through 2032, because of a resurgence of TB cases, particularly among vulnerable populations such as immigrants, refugees, and those with compromised immune systems. Increased efforts by European health authorities to achieve early detection and treatment are driving the need for advanced diagnostic tools. Additionally, the rising incidence of multidrug-resistant TB (MDR-TB) in the region is prompting the adoption of more accurate and timely diagnostics. Public health initiatives and funding aimed at eradicating TB further support the expansion of diagnostic services across Europe.
Request for Report Customization @ https://www.Gminsights.Com/roc/7892
Tuberculosis Diagnostics Test Market Players
Major players in the tuberculosis diagnostics test industry include Abbott Laboratories, Becton, Dickinson and Company (BD), bioMerieux SA, Cepheid (Danaher Corporation), F. Hoffmann-La Roche Ltd., Hologic, Inc., Hain Lifescience GmbH, Oxford Immunotec (PerkinElmer), Qiagen N.V., Roche Molecular Systems Inc., Siemens Healthineers AG, and Thermo Fisher Scientific Inc.
In February 2023, Thermo Fisher Scientific launched real-time PCR kits in India for detecting a range of infectious diseases, including Multi-Drug-Resistant Tuberculosis (MTB MDR) and HIV. Approved by the Central Drugs Standard Control Organization (CDSCO) and produced with Mylab Discovery Solutions, these kits boost the company's market presence and revenue in India.
Partial Table of Contents (ToC) of the report:
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Base estimates and working
1.3 Forecast calculations
1.4 Data sources
1.4.1 Primary
1.4.2 Secondary
1.4.2.1 Paid sources
1.4.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global tuberculosis diagnostics test market 3600 synopsis, 2018 – 2032
2.1.1 Regional trends
2.1.2 Test type trends
2.1.3 End-use trends
Chapter 3 Tuberculosis Diagnostics Test Industry Insights
3.1 Industry ecosystem analysis
3.2 Technology landscape
3.3 Regulatory landscape
3.4 Industry impact forces
3.4.1 Growth drivers
3.4.1.1 Rising burden of tuberculosis globally
3.4.1.2 Advancement in tuberculosis diagnostics techniques
3.4.1.3 Increasing awareness and screening programs regarding tuberculosis
3.4.1.4 Surge in Point-of-Care testing (POCT)
3.4.2 Industry pitfalls and challenges
3.4.2.1 Limited sensitivity and specificity
3.4.2.2 Stringent regulatory scenario
3.5 Growth potential analysis
3.5.1 By test type
3.5.2 By end-use
3.6 Porter's analysis
3.7 PESTEL analysis
Browse more diagnostic devices industry reports @ https://www.Gminsights.Com/industry-reports/diagnostic-devices/82
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
CONTACT: Contact Us: Aashit Tiwari Corporate Sales, USA Global Market Insights Inc. Toll Free: +1-888-689-0688 USA: +1-302-846-7766 Europe: +44-742-759-8484 APAC: +65-3129-7718 Email: sales@gminsights.Com Read More News @ https://ibmag.ComView comments
Comments
Post a Comment